Showing results (31-40 of 132) with videos related to
Sort By:
Pageof 14
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN TrialJamie E Chaft, Mark Dunphy, Jarushka Naidoo, et al.The Lancet. Oncology|February 10, 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyScott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.Lung Cancer (Amsterdam, Netherlands)|October 19, 2025
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancersPrashasti Agrawal, Julia Rotow, Gaetano Rocco, et al.The Lancet. Oncology|January 4, 2014
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointMatthew D Hellmann, Jamie E Chaft, William N William, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2018
Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell CarcinomaYang Qu, Katsura Emoto, Takashi Eguchi, et al.Cell|March 4, 2014
Serpins promote cancer cell survival and vascular co-option in brain metastasisManuel Valiente, Anna C Obenauf, Xin Jin, et al.Annals of Surgery|March 27, 2018
Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic DiseaseAshley E Russo, Brian R Untch, Mark G Kris, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 3, 2024
Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancerMatthew T McMillan, Annemarie Shepherd, Alissa J Cooper, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2021
The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant TumorsNarek Shaverdian, Michael Offin, Annemarie F Shepherd, et al.Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancerJamie E Chaft, Ibiayi Dagogo-Jack, Fernando C Santini, et al.Pageof 14